To compare the safety and efficacy of a simpler titration algorithm for insulin degludec/liraglutide (IDegLira) with that used in previous DUAL trials in insulin-naïve patients with type 2 diabetes.
| INTRODUCTION
The progressive nature of type 2 diabetes means that the majority of patients may eventually require insulin therapy, 1,2 but insulin initiation is often delayed for several years until glycaemic control has deteriorated well beyond guideline targets. 3 Reasons for this clinical inertia include patient fear of unwanted side effects such as hypoglycaemia and weight gain, fear of injections, the belief that quality of life will worsen considerably and the belief that adherence to increasingly complex regimens will prove too challenging. 4, 5 However, evidence of an inverse correlation between regimen complexity and patient adherence 6, 7 suggests that simpler treatment regimens could do much to tackle clinical inertia.
In recent years, the effectiveness of combining basal insulin therapy with glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy has been demonstrated, and is reflected in the joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. 8 GLP-1RAs stimulate insulin secretion while suppressing glucagon release in a glucosedependent manner, 9 and are associated with weight loss and a low risk of hypoglycaemia; however, transient gastrointestinal (GI) side effects are common with initial GLP-1RA therapy. 10, 11 Once-daily GLP-1RAs can be combined with once-daily basal insulins as fixedratio combination products such as insulin degludec with liraglutide (IDegLira) and insulin glargine with lixisenatide (iGlarLixi), [12] [13] [14] [15] [16] [17] [18] thereby simplifying treatment escalation. The clinical utility of IDegLira has been demonstrated previously in patients with type 2 diabetes uncontrolled by oral antidiabetic drugs (OADs), GLP-1RA therapy and basal insulin therapy in the phase 3 DUAL trials I to V. [13] [14] [15] [16] [17] Results from DUAL I, a phase 3a trial, 13, 14 demonstrate that IDegLira combines the clinical advantages and limits the principal side effects of basal insulin (weight gain, hypoglycaemia) and GLP-1RA (GI side effects) therapy, and is insulin-sparing as compared to basal insulin alone.
Alternative titration algorithms can simplify regimen complexity, and thereby help empower patients to manage their diabetes more conveniently and effectively, as demonstrated in AT.LANTUS 19 and the INSIGHT study. 20 The present trial assessed whether similar glycaemic control and tolerability could be achieved with IDegLira using a simpler, more pragmatic once-weekly titration algorithm in insulinnaïve patients with type 2 diabetes uncontrolled with OADs than previously employed in the DUAL clinical programme. Therefore, this trial investigated the safety and efficacy of IDegLira titrated once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) measurements, vs twice-weekly titration, based on the mean of 3 pre-breakfast PG readings (ie, 6 measurements and 2 dose adjustments per week).
| RESEARCH DESIGN AND METHODS

| Study design and participants
This phase 3b, 32-week, randomized, open-label, parallel-group trial was conducted at 80 sites in 9 countries (Table S1 , Appendix S1) (Table S2 , Appendix S1 lists all inclusion and exclusion criteria).
| Randomization and masking
Participants were randomized using a central interactive voice/web system in a 1:1 ratio to receive once-daily, subcutaneous injections of IDegLira (100 units/mL IDeg: 3.6 mg/mL liraglutide; 3 mL prefilled PDS290 pen-injector; Novo Nordisk, Bagsvaerd, Denmark) titrated either once weekly (n = 210) or twice weekly (n = 210) ( Figure S1 , Appendix S1
). An external independent event adjudication committee (EAC) performed ongoing adjudication and standardized assessment of selected events. An independent committee of thyroid experts regularly monitored plasma calcitonin levels.
The trial was open-label as all patients in both treatment arms received IDegLira and it was the 2 different titration algorithms that were compared. Furthermore, the frequency of self-measured plasma glucose (SMPG) measurements was different in the 2 arms, making blinding unfeasible.
| Procedures
Metformin was maintained at pre-trial dose and frequency, unless there was a safety concern. At randomization, IDegLira was initiated 
| Outcome measures
The primary endpoint was change from baseline in HbA1c after (inclusive) were classified as nocturnal ( Figure S2 , Appendix S1).
Patient-reported outcomes (PROs) were measured using the 
| Statistical analyses
The trial was powered for the primary objective of demonstrating non-inferiority with respect to change in HbA1c using a one-sided t- Non-inferiority for the primary endpoint was to be investigated using 3 pre-specified sensitivity analyses. The primary efficacy analysis based on FAS was to be repeated on: (1) the PP analysis set; 
| RESULTS
| Patients
Of 613 patients screened, 420 were randomized and 395 completed the trial ( Figure S3 , Appendix S1). Completion rates were 91% and 97% for once-weekly and twice-weekly titration, respectively. Six patients (2.9%) had AEs leading to withdrawal in the IDegLira onceweekly titration group and 2 patients (1.0%) in the IDegLira twice-weekly titration group. One patient in the IDegLira once-weekly titration group met the withdrawal criterion of exceeding pre-defined fasting SMPG or FPG limits. Treatment groups were well matched with respect to demographic and baseline characteristics (Table 1) .
| Glucose control
After 32 weeks of treatment, the observed mean (SD) HbA1c Figure 1A ), confirming non-inferiority of once-weekly compared with twice-weekly titration of IDegLira. The MMRM sensitivity analyses in the PP and CAS were in agreement with the primary analysis. When using an ANOVA model based on LOCF-imputed data, however, the 95% CIs exceed the non-inferiority margin (Table S3 , Appendix S1).
Consistent with the reduction in HbA1c, similar proportions of patients (no significant differences) achieved glycaemic targets and the composite endpoints for HbA1c targets with no hypoglycaemia. Similar proportions of patients achieved HbA1c targets and composite endpoints for HbA1c targets with no hypoglycaemia, with almost 90% of patients in both treatment groups achieving HbA1c < 7.0% (Table 2) . Mean daily insulin dose was 11 units at week 1 and increased steadily throughout the trial for both treatment groups. In accordance with the titration regimen, mean insulin dose increased more rapidly in the twice-weekly titration group, but insulin doses were similar between treatment groups by week 21, and the mean IDegLira dose at 32 weeks was 41 dose steps (41 units IDeg and 1.48 mg Lira) for both treatment groups ( Figure 1C) . Importantly, for each treatment group, the actual and recommended daily doses were similar for each of the two arms ( Figure S5 , Appendix S1), indicating good overall compliance with titration guidance.
IDegLira was associated with weight loss with both titration algorithms; mean (SD) weight change was −1.0 kg (4.2) for once-weekly vs −2.0 kg (4.9) for twice-weekly titration, corresponding to a statistically significant ETD of 1.09 kg [0.22; 1.96] 95% CI , P = .014 ( Figure 1D ).
| Safety endpoints
Severe or BG-confirmed symptomatic hypoglycaemia occurred in 5.7% and 16.2% of patients in the once-weekly and twice-weekly titration groups, respectively, with rates of 0.16 events/patient-year of exposure (PYE) for once-weekly and 0.76 events/PYE for twice-weekly titration. The mean cumulative plot is shown in Figure 1E . One patient experienced severe hypoglycaemia (IDegLira twice-weekly titration). Rates of nocturnal severe or BG-confirmed symptomatic hypoglycaemia were also low in both groups, and lower with once-weekly titration (Table 3) .
The overall AE rates were similar in the IDegLira once-weekly and twice-weekly titration arms ( Table 4 ). The majority of AEs were non-serious, mild in severity and unlikely to be related to trial products, as judged by the investigator; hence, treatment was considered to be well tolerated. The rate of AEs judged to be probably related to trial product was low for both treatment groups: 12.3 vs 11.8 events/100 PYE for once-weekly vs twice-weekly titration of IDegLira, respectively, with the most common AEs considered possibly or probably related to trial product being nausea, constipation, diarrhoea, increased lipase and headaches. Overall, these AEs occurred with similar frequency in both treatment groups. The only AEs to occur in ≥5% of patients were nausea (5.3% vs 5.2% of patients in once-weekly vs twice-weekly titration groups) and nasopharyngitis (6.2% vs 4.3% of patients in once-weekly vs twice-weekly titration groups). The rates of serious AEs were low (Table 4) , with no obvious pattern in type of events, and no single type of serious AE occurred in ≥1% of patients. There were no differences in pulse rate or diastolic or systolic blood pressure between treatment groups (Table S4 , Appendix S1).
There was one confirmed adjudicated major adverse cardiovascular event (MACE) in each treatment group (myocardial infarction in the once-weekly titration group and a fatal event in the twice-weekly titration group). There were 3 confirmed adjudicated neoplasm events, only one of which was malignant (female reproductive).
| Patient-reported outcomes
There was no significant difference between the 2 titration algorithms in improvement of TRIM-D total score or any TRIM-D subdomain score, or of physical component score and subdomains of the SF-36v2 questionnaire. Patients in the IDegLira once-weekly titration group reported significantly greater improvements than patients using the twice-weekly titration algorithm in the vitality, social functioning and mental health subdomain scores of the mental health component of the SF-36v2 questionnaire (all P < .05). There was no statistically significant treatment difference for overall mental score of SF-36v2 ( Figure S4 , Appendix S1). Treatment difference analysed using MMRM based on FAS. E, Severe or BG-confirmed symptomatic hypoglycaemia. Mean cumulative function based on SAS (IDegLira 1WT/IDegLira 2WT: n = 209/210). Because of the study design, with more SMPG measurements taken in the 2WT group, the number of hypoglycaemic episodes is expected to be biased towards more hypoglycaemic episodes in the 2WT group compared with the 1WT group. Hence, solely descriptive analysis was applied. The MMRM model included treatment, visit, region and previous OAD treatment as factors, and baseline value as covariate. Interactions between visit and all other factors and the covariate are also included in the model. AACE, American Association of Clinical Endocrinologists; ADA, American Diabetes Association; BG, blood glucose; EASD, European Association for the Study of Diabetes; ETD, estimated treatment difference; FAS, full analysis set; FPG, fasting plasma glucose; IDegLira, insulin degludec/ liraglutide; LS Mean, least square mean; MMRM, mixed model for repeated measurement; OAD, oral antidiabetic drug; SAS, safety analysis set; SMPG, self-measured plasma glucose; 1WT, once-weekly titration; 2WT, twice-weekly titration.
| DISCUSSION
values. This is probably caused by the fact that there were more patients who withdrew before week 12 in the IDegLira once-weekly titration group compared with the twice-weekly titration group. FPG reductions and proportion of patients achieving HbA1c targets and composite endpoints were also similar between treatment groups. Rates of severe or blood glucose-confirmed symptomatic hypoglycaemia were low for both titration algorithms. The greater divergence in the curves observed during weeks 6 to 16 ( Figure 1E ) may be related to the discrepancy in drug exposure between the 2 titration groups. Nevertheless, even from week 22 onwards, when both groups had reached final dose, there still appeared to be a divergence in the hypoglycaemia curves. This is probably an artefact attributable to the more frequent BG monitoring in the twice-weekly titration group.
In general, IDegLira was well-tolerated when added to treatment with metformin AE pioglitazone. There were few different types of AEs reported for IDegLira and they were no different from what was expected from its mono-components -insulin degludec and liraglutide. 16, 24, 25 Patients often cite the expected impact of burdensome regimens on quality of life as a barrier to insulin initiation/intensification, Odds ratios are from a logistic regression model based on FAS using logit link with treatment, region and previous OAD treatment as fixed factors, and baseline HbA1c as covariate.
Abbreviations: BG, blood glucose; CI, confidence interval; FAS, full analysis set; IDegLira, insulin degludec/liraglutide; OAD, oral antidiabetic drug; 1WT, once-weekly titration; 2WT, twice-weekly titration.
1 Severe or BG-confirmed symptomatic hypoglycaemia is based on hypoglycaemic episodes during a patient's last 12 weeks of treatment. Data based on safety analysis set. There was 1 event of myocardial infarction (1WT) and 1 event of CV death (2WT). One malignant female reproductive event and 1 benign colorectal event were confirmed in the 1WT group, and 1 benign head and neck event was confirmed in the 2WT group. There were no confirmed thyroid or pancreatitis events.
Abbreviations: CV, cardiovascular; IDegLira, insulin degludec/liraglutide; PYE, patient-year of exposure; 1WT, once-weekly titration; 2WT, twiceweekly titration. Abbreviations: BG, blood glucose; E, number of events; IDegLira, insulin degludec/liraglutide; n, number of patients with at least 1 event; R, rate of events per 100 patient-years of exposure; %, percentage of patients; 1WT, once-weekly titration; 2WT, twice-weekly titration.
titration. There was no significant difference in the Compliance and Treatment burden subdomains of TRIM-D. Nevertheless, both treatment arms benefited from improvements in PROs, and a substantial difference between the titration groups might not be expected, given that large proportions of patients in each treatment arm achieved HbA1c targets with no hypoglycaemia. However, these results do suggest that patients who have resisted insulin initiation thus far, because they believe it will greatly impact their quality of life, might prefer initiation of IDegLira using once-weekly titration. The once-weekly titration algorithm might also have the advantage of reduced healthcare costs as a result of the fewer number of BG test strips required. This, together with a titration algorithm that can be patient-managed, might make IDegLira a more attractive option earlier on in a patient's disease trajectory, thereby facilitating the adoption of an approach aimed at addressing the underlying pathophysiology. This approach is particularly important in primary care because the earlier in the progression of disease this approach is introduced, the greater the impact it can have on slowing progressive beta-cell failure. 27, 28 Therefore, the development and evaluation of simple titration algorithms, such as the one described here for IDegLira, is of great importance.
An inherent limitation of randomized controlled trials is that the clinical applicability of the results is limited to those who fit the inclusion and exclusion criteria and the settings in which they were assessed. In this case, patients were to be able and willing to adhere to the protocol and they were then advised on the importance of adhering to trial protocol at every visit with the investigator. The extent to which this will differ from clinical practice is unclear, but the results demonstrate that either titration regimen can be employed safely and effectively in insulin-naïve patients with T2D uncontrolled on OADs.
In conclusion, a pragmatic IDegLira titration algorithm with onceweekly dose adjustments based on 2 PG readings resulted in a safety and glycaemic efficacy profile similar to that with twice-weekly adjustments based on 3 preceding PG values. 13, 14 This pragmatic titration algorithm can therefore be considered on an individual basis for insulin-naïve patients uncontrolled on OADs.
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